Glycostem obtained the Tissue Bank License, to support the production of their lead investigational product oNKord®. Currently oNKord® is produced with cord blood from UK. The Tissue Bank License makes it possible to continue production after the Brexit transition period, to use raw materials from other countries outside the EU, for example US, in the future. They are continuing treating AML patients in the oNKord phase I/phase II clinical trial.